Theravance Biopharma, Inc.
US ˙ NasdaqGM ˙ KYG8807B1068

SecurityTBPH / Theravance Biopharma, Inc.
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership289,473 shares
Latest Disclosed Value $ 4,698,147
Qube Research & Technologies Ltd reports 38.87% decrease in ownership of TBPH / Theravance Biopharma, Inc.

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 289,473 shares of Theravance Biopharma, Inc. (US:TBPH) valued at $4,698,147 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 473,498 shares of Theravance Biopharma, Inc.. This represents a change in shares of -38.87% during the quarter. The current value of the position is $4,738,673 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 289,473 -184,025 -38.87 4,698 -46.97 0.0052
2026-02-17 2025-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 473,498 262,450 124.36 8,859 187.54 0.0090
2025-11-14 2025-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 211,048 5,768 2.81 3,081 36.09 0.0032
2025-08-14 2025-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 205,280 91,341 80.17 2,264 122.62 0.0023
2025-05-15 2025-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 113,939 113,939 1,017 0.0012
2021-02-16 2020-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 0 -17,094 -100.00 0 -100.00
2020-11-12 2020-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 17,094 3,971 30.26 253 -8.00 0.0036
2020-08-14 2020-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 13,123 13,123 275 0.0040
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.